More recently, adjuvant immunotherapy agents targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed death-1 (PD-1) regulatory pathway have been used successfully as adjuvant immunotherapy agents for metastatic melanoma. Here, CTLA4 is linked to metastatic melanoma.